Introduction: Feline mast cell tumours (FeMCTs), overall Accounting for 1e9% of feline neoplasms, are characterized by a highly variable biological behaviour. Frequent post- surgical recurrence, de-novo development of multiple tumours and concurrent visceral and cutaneous involvement justify uncertainty in differentiating benign from malignant forms, with tendency to systemic spread. Materials and Methods: A series of FeMCTs with variable clinical presentation were examined by histology (cell morphology, differentiation, growth pattern, mitotic activity), CD117 immunohistochemistry and c-Kit mutation analysis (exons 8, 9 and 11). Data were correlated with clinical records (clinical signs, TNM stage, haematological abnormalities and 2-year follow-up) to assess their prognostic significance. Results: Twenty cats with 10 solitary cutaneous, five multiple cutaneous and five systemic MCTs were included; nine cats were still alive at the end of the follow-up period. Overall, 29 tumour samples were examined. There were 21 well-differentiated, three pleomorphic and five atypical FeMCTs; mean mitotic activity was 9/10 high power fields. Low to high CD117 expression was observed in 18 cases. Further c-Kit mutations, beside those previously described in FeMCT, were found. Conclusions: This study investigated the effects of c-Kit dysregulation on FeMCT biological behaviour and also potentially allowed the identification of those patients that may benefit from molecular targeted therapies.

KIT receptor dyregulations in feline mast cell tumours and systemic mastocytosis.

SABATTINI, SILVIA;GENTILINI, FABIO;CAPITANI, OMBRETTA;BETTINI, GIULIANO
2012

Abstract

Introduction: Feline mast cell tumours (FeMCTs), overall Accounting for 1e9% of feline neoplasms, are characterized by a highly variable biological behaviour. Frequent post- surgical recurrence, de-novo development of multiple tumours and concurrent visceral and cutaneous involvement justify uncertainty in differentiating benign from malignant forms, with tendency to systemic spread. Materials and Methods: A series of FeMCTs with variable clinical presentation were examined by histology (cell morphology, differentiation, growth pattern, mitotic activity), CD117 immunohistochemistry and c-Kit mutation analysis (exons 8, 9 and 11). Data were correlated with clinical records (clinical signs, TNM stage, haematological abnormalities and 2-year follow-up) to assess their prognostic significance. Results: Twenty cats with 10 solitary cutaneous, five multiple cutaneous and five systemic MCTs were included; nine cats were still alive at the end of the follow-up period. Overall, 29 tumour samples were examined. There were 21 well-differentiated, three pleomorphic and five atypical FeMCTs; mean mitotic activity was 9/10 high power fields. Low to high CD117 expression was observed in 18 cases. Further c-Kit mutations, beside those previously described in FeMCT, were found. Conclusions: This study investigated the effects of c-Kit dysregulation on FeMCT biological behaviour and also potentially allowed the identification of those patients that may benefit from molecular targeted therapies.
ESVP/ECVP Proceedings 2011
55
55
JOURNAL OF COMPARATIVE PATHOLOGY
Sabattini S; Guadagni-Frizzon M; Turba ME; Gentilini F; Capitani O; Bettini G
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/113179
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact